Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 0.00 | 0.00 | 0.00 | 1.19M |
| Change in Net Operating Assets | 1.16M | 3.66M | -3.77M | -10.25M | 400.70K |
| Cash from Operations | -2.22M | -291.50K | -4.23M | -11.27M | -275.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 5.07M | -112.30K |
| Cash from Investing | -- | 0.00 | 0.00 | 5.07M | -112.30K |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 300.00K |
| Total Debt Repaid | -- | 0.00 | 0.00 | -300.00K | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 0.00 | 10.00M |
| Repurchase of Common Stock | -150.50K | -270.30K | -84.10K | -5.07M | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | 9.02M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -1.53M | 726.30K |
| Cash from Financing | -150.50K | -270.30K | -84.10K | -6.90M | 20.05M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.37M | -561.90K | -4.32M | -13.09M | 19.66M |